HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $16.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on ESPR. JMP Securities reiterated a “market outperform” rating and issued a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Esperion Therapeutics has a consensus rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Price Performance

ESPR stock opened at $1.69 on Thursday. The company has a 50 day moving average price of $1.84 and a 200 day moving average price of $2.07. Esperion Therapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $3.94. The stock has a market capitalization of $334.36 million, a PE ratio of -2.64 and a beta of 1.04.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors have recently modified their holdings of the business. Cibc World Markets Corp acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $39,000. SJS Investment Consulting Inc. acquired a new position in shares of Esperion Therapeutics during the 4th quarter worth approximately $55,000. Crestline Management LP bought a new stake in shares of Esperion Therapeutics during the 4th quarter worth approximately $63,000. SLT Holdings LLC acquired a new stake in shares of Esperion Therapeutics in the 4th quarter valued at approximately $66,000. Finally, Foundations Investment Advisors LLC increased its holdings in Esperion Therapeutics by 48.6% during the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 9,872 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.